Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD
About this study
BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to validate data regarding markers of resilience toward AD pathophysiological process discovered in an upstream project called AD-Resilience.
- Condition
- Alzheimer Disease
- Tested
- Blood sample, Neuropsychological battery tests
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Who can join
- Age
- 50 to 90 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 11
- Minimum age: 50 years
- Maximum age: 90 years
- Study condition: Alzheimer Disease
- Diagnosis of AD according to IWG-2 2014 criteria
- Age 50-90 year old
- Affiliated or beneficiary of a social security scheme
- MMSE ≥ 20
- Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio according to local cut-offs
- Abnormal CSF phosphorylated and total Tau according to local cut-offs
- Ability to pass neuropsychological assessments
- Availability of a brain MRI with T1 volumetric sequence performed within 1 year
Exclusion 3
- Other cause of dementia
- Participation in an AD therapeutic clinical trial
- Protected adults (including individual under guardianship by court order),
Where
1 site, 1 recruiting
Hôpital Cochin
Paris, France
Contact
-
Olivier HANON, MD, PhD
+ 1 44 08 33 81 olivier.hanon@aphp.fr
-
Valérie PLENCE, MSc
+33 1 54 41 11 78 valerie.plence@aphp.fr
Potential match only. Final eligibility is determined by the study team.